

von Willebrand Factor Concentrates

Manufacturer	Product	Type	Indication
CSL Behring	Humate-P®	Plasma-derived FVIII/VWF complex. Average ratio of VWF:RCo to FVIII is 2.4:1.	Control of bleeding in adults and children with severe type 3 VWD; and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis.
Grifols	Alphanate®	Plasma-derived FVIII/VWF complex. Ratio of VWF:RCo to FVIII is 1.3:1 (varies by lot).	Control and prevention of bleeding in adults and children with hemophilia A; and adults and children with VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for patients with type 3 VWD undergoing major surgery.
Octapharma	wilate®	Plasma-derived FVIII/VWF complex. Ratio of VWF:RCo to FVIII is 1:1.	Control of bleeding in adults and children with type 3 VWD; and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis. Control of bleeding in adolescents and adults with hemophilia A. Indicated for prophylaxis and on-demand treatment .
Takeda	Vonvendi®	Recombinant VWF (contains no FVIII)	Control of bleeding in adults with VWD. Contains VWF only, no FVIII. Administer first dose with a recombinant FVIII-only product if FVIII baseline levels are below 40% or are unknown (this applies to all type 3 VWD patients).

VWD: von Willebrand disease. VWF: von Willebrand factor. RCo: ristocetin cofactor. VWF:RCo: von Willebrand factor ristocetin cofactor assay.

© 2023 LA Kelley Communications, Inc. All rights reserved.

Additional von Willebrand Disease Medicines

Manufacturer	Product	Type	Indication
Generic drug available from Pfizer, Amneal, Carnegie, Camber & others	epsilon aminocaproic acid [EACA] ; available as injection, oral solution or tablets	Antifibrinolytic	Helps retain blood clots by inhibiting the action of enzymes that break down clots (fibrinolysis). Antifibrinolytics do not help form clots and for type 3 VWD, are useful only in after infusion of FVIII/VWF concentrate. Useful for mucous membrane bleeds, as in the mouth or nose, where clots are quickly broken down. Oral solution may also be used as a mouthwash. Short-term use (less than 10 days).
Ferring Pharmaceuticals	Stimate™ (brand name for desmopressin acetate nasal spray, 1.5 mg/mL) Out of production until 2024	Synthetic form of natural hormone vasopressin	Indicated only for type 1 VWD with factor VIII levels greater than 5%; <i>not for infants</i> . Increases circulating levels of FVIII and VWF by releasing stores from endothelial cells lining blood vessels. Short-term use (a few days). Each subsequent use within 48 hours results in a lower response. Full response usually restored about a week after last use, but some patients may take up to 6 weeks after last use for stores of factor VIII and VWF to be replaced. Do not use if you have severe kidney disease or have ever had hyponatremia (low sodium levels).
Ferring Pharmaceuticals Generic from Dr. Reddy's Laboratories	DDAVP® Injection (brand name for desmopressin acetate, 4 mcg/mL) Brand name out of production until 2024	Synthetic form of natural hormone vasopressin	Indicated only for type 1 VWD factor with VIII levels greater than 5%; for ages over 3 months. Increases circulating levels of FVIII and VWF by releasing stores from endothelial cells lining blood vessels. Short-term use (a few days). Each subsequent use within 48 hours results in a lower response. Full response usually restored about 1 week after last use, but some patients may take up to 6 weeks after last use for stores of factor VIII and VWF to be replaced. Do not use if you have severe kidney disease or have ever had hyponatremia (low sodium levels).
Amring Pharmaceuticals	Lysteda™ (brand name for tranexamic acid [TXA] tablets)	Antifibrinolytic	Indicated for heavy menstrual bleeding in women with VWD. Short-term use (less than 8 days). Helps retain blood clots by inhibiting the action of enzymes that break down clots.
Pfizer	Cyklokapron® Injection (brand name for tranexamic acid [TXA])	Antifibrinolytic	Not indicated for use in VWD patients, but widely used off-label in VWD patients . Helps retain blood clots by inhibiting the action of enzymes that break down clots. Ten times more potent than aminocaproic acid. Short-term use (less than 8 days).

© 2023 LA Kelley Communications, Inc. All rights reserved.